Contact us

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now
  • en
  • cn

    • English

    • English
    • Chinese

    © 2021- edbi. All rights reserved.